This focused biopharma company unites science, technology, and talent to advance ahead of disease. Their research and development efforts concentrate on four key therapeutic areas: respiratory, immunology and inflammation; oncology; HIV; and infectious diseases. The company aims to positively impact global health by delivering innovative products and improving access to healthcare worldwide.
Funding
Funding not disclosed
Founders
Product
Problem
Many cancer patients receive treatments that ultimately prove ineffective, leading to wasted time and potential disease progression. Determining the most effective treatment option for an individual tumor before initiating therapy remains a significant challenge in oncology.
Solution
ASC Oncology employs Reverse Clinical Engineering® to analyze patient tumor samples in vitro, identifying the most promising treatment options based on the unique characteristics of each tumor. By creating "avatars" of the patient's tumor using 3D cell cultures called tumor organoids, the platform tests the efficacy of various cancer drugs directly on the patient's own tumor cells. This approach provides clinicians with data-driven insights to select the treatment with the highest probability of success, potentially avoiding ineffective therapies and improving patient outcomes. The Reverse Clinical Engineering® test procedure delivers _in-vitro_ data, allowing physicians to determine the treatment option with the greatest potential impact. The goal is to close the gap between modern cancer research and practical application, and to improve the quality of life and survival chances of each individual patient.
Target Audience
The primary audience includes oncologists and other physicians treating patients with solid tumors, as well as cancer patients seeking personalized treatment options.
Features
- Utilizes Reverse Clinical Engineering® to analyze tumor samples in vitro
- Creates patient-derived 3D tumor organoids (PD3D®) to model individual tumors
- Tests the efficacy of various cancer drugs directly on patient-specific tumor models
- Provides data-driven insights to guide treatment selection
- Aims to identify the most effective therapy and avoid ineffective treatments
- Offers add-on options such as sequencing or proteomic analysis to further refine treatment strategies
- Delivers a comprehensive report within approximately 28 days from sample receipt